Skip to main content
. 2021 May 14;12(5):489. doi: 10.1038/s41419-021-03788-4

Fig. 7. Decrease of cancer recurrence, monocytic MDSCs, and MMP14 by TLR4 inhibition in mouse liver IRH with tumor recurrence model.

Fig. 7

A Reduced tumor progression by the treatment of TLR4 inhibitors (CLI095) compared to no treatment wild type mice; scale bars: 500 μm. B The obvious decline of infiltrated CD31 positive cells in tumor tissue by TLR4 inhibition; scale bars: 50 μm. C Decreased liver monocytic MDSCs by TLR4 inhibition. D Less infiltrated MMP14 in the mice with the treatment of TLR4 inhibitors; scale bars: 100 μm. E Research summary: monocytic MDSCs were mobilized and recruited to liver graft through CXCL10/TLR4/MMP14 signaling during acute phase injury, and to promote HCC recurrence after transplantation. N = 5/group; error bars indicate standard error of mean; *p < 0.05, **p < 0.01, ***p < 0.001. MDSC myeloid-derived suppressor cell, MMP14 matrix metallopeptidase 14, IRH ischemia/reperfusion plus major hepatectomy, WT wild type.